A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. Benefit and weak benefit are separate tags. Weak benefit is the tag “Significant, low-quality evidence”. No harm tag ≠ safe. Floors are chosen from efficacy studies. Risks live on the dose page and in the interaction checker. “Not stated in the abstract” means the PubMed abstract we checked did not name a funder. It does not mean the full paper is silent. Copying a card copies the dose-page link, the safety link, and these limits, under CC BY 4.0. The dataset is the same file. The retraction radar, the funding meter, and the enforcement log are the other columns on this desk.

26ingredients

54floors

24benefit

4weak benefit

0harm tags in floors

26uncertain

This is not a success rate. Guides choose which studies become floors. No harm tag ≠ safe. A zero in “harm tags in floors” means no floor was tagged harm. It does not mean the ingredient is safe.

5-HTP

Supplement Brief fact box · CC BY 4.0

Dose page
5-HTP fact box
Benefit

Antidepressant add-on (300 mg/day)

  • 300 mg
  • over 28 days
  • daily
  • n=26
  • limited evidence
  • Benefit shown
  • Not stated in the abstract

300 mg/day added to chlorimipramine 50 mg/day in hospitalized depression, double-blind against chlorimipramine plus placebo, for 28 days. Two patients on chlorimipramine plus placebo dropped out. Supervised add-on context only, never a basis for stacking on top of serotonergic medication without a prescriber.

PMID 6381336

Weak benefit

Depression trial in Parkinson's disease (50 mg/day)

  • 50 mg
  • over 4 weeks
  • daily
  • n=25
  • limited evidence
  • Significant, low-quality evidence
  • Not stated in the abstract

50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide.

PMID 32067288

Obesity trial (900 mg/day)

  • 900 mg
  • over two consecutive 6-wk periods
  • daily
  • n=20
  • limited evidence
  • Significant, low-quality evidence
  • Not stated in the abstract

900 mg/day in 20 obese adults randomly assigned to 5-HTP or placebo, across two consecutive double-blind 6-week periods. No diet was prescribed during the first period. A 5040-kJ/d diet was recommended for the second. Significant weight loss, lower carbohydrate intake, and earlier satiety were seen on 5-HTP during both periods. The authors report good tolerance.

PMID 1384305

Harm

No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe. Safety text on the dose page.

Uncertain

No floor is tagged as missed, secondary-only, or untagged.

A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe.
5-HTP
Dose page: https://supplementbrief.com/dose/5-htp/
Safety: https://supplementbrief.com/dose/5-htp/#dose-red-flags-heading
Supplement Brief dose card. CC BY 4.0. https://supplementbrief.com/data-desk/dose-cards/

A floor is the dose used in a cited study. It is not a minimum effective dose and it is not a recommendation. This card is not a success rate. A count per 100 people is absent. No harm tag ≠ safe.

Benefit
Antidepressant add-on (300 mg/day)
300 mg · over 28 days · daily · n=26 · limited evidence · Benefit shown · Not stated in the abstract
300 mg/day added to chlorimipramine 50 mg/day in hospitalized depression, double-blind against chlorimipramine plus placebo, for 28 days. Two patients on chlorimipramine plus placebo dropped out. Supervised add-on context only, never a basis for stacking on top of serotonergic medication without a prescriber.
PMID 6381336

Weak benefit
Depression trial in Parkinson's disease (50 mg/day)
50 mg · over 4 weeks · daily · n=25 · limited evidence · Significant, low-quality evidence · Not stated in the abstract
50 mg/day for 4 weeks in a randomized double-blind placebo-controlled crossover trial in Parkinson's disease depression; significant HDRS improvement, no effect on apathy, and the authors call it preliminary. A single small trial in one population, cited by our 5-HTP with SSRIs guide.
PMID 32067288

Obesity trial (900 mg/day)
900 mg · over two consecutive 6-wk periods · daily · n=20 · limited evidence · Significant, low-quality evidence · Not stated in the abstract
900 mg/day in 20 obese adults randomly assigned to 5-HTP or placebo, across two consecutive double-blind 6-week periods. No diet was prescribed during the first period. A 5040-kJ/d diet was recommended for the second. Significant weight loss, lower carbohydrate intake, and earlier satiety were seen on 5-HTP during both periods. The authors report good tolerance.
PMID 1384305

Harm
No harm tag ≠ safe. No floor in this file carries a harm tag. That is not a finding that the ingredient is safe.

Uncertain
No floor is tagged as missed, secondary-only, or untagged.